A triple-hormone-receptor agonist studied for its effects on body weight and metabolic markers, the furthest along of the newer “triple agonist” peptides.
Reviewed for accuracy · Last reviewed July 7, 2026Retatrutide activates three separate metabolic receptors at once (GLP-1, GIP, and glucagon), which is why it's drawn so much attention in weight and metabolic research: the combination appears to affect appetite, energy expenditure, and blood sugar regulation simultaneously rather than through a single pathway.
It's administered as a once-weekly subcutaneous injection, typically starting at a low dose and titrating upward over several weeks to manage side effects.
The published Phase 2 obesity trial escalated once-weekly subcutaneous doses through 1 mg, 4 mg, 8 mg, and 12 mg. Retatrutide is investigational, so there is no approved prescribing dose.
Read the full Retatrutide dosage guide →In that trial the most common adverse events were gastrointestinal (nausea, diarrhea, vomiting, constipation), generally mild to moderate and dose-related.
Read the full Retatrutide side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 3–4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.